Background: Although hyperhidrosis is a common and burdensome condition, little is known about the population-based prevalence. Objective: To evaluate the epidemiology, disease burden and medical care of hyperhidrosis in German adults. Methods: Employees of fifty-two companies underwent skin screenings and interviews including hyperhidrosis questions. Results: 14,336 individuals were investigated (36% women, mean age 42 years) of whom 2,340 (16.3%) reported hyperhidrosis, including 869 (6.1%) with frequent or continuous disturbing sweating. 28% showed focal hyperhidrosis, whilst 68% had a generalized condition. Predictors of hyperhidrosis were male gender and concomitant drug medication. Moreover, persons with psoriasis and with metabolic comorbidity were at increased risk. Only 27% of those with focal hyperhidrosis had consulted a physician, and only 28% used prescribed medication or self-medication. Conclusion: Hyperhidrosis is a frequent skin condition predicted by medical and personal factors. In spite of the disease burden, few individuals utilize medical care. Affected individuals should be encouraged to refer to a dermatologist.

Keywords:
Hyperhidrosis, Epidemiology, Prevalence, Disease burden, Dermatology, Health services research
1.
Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, Ahn S, Stolman LP: Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004;51:274-286.
2.
Naumann MK, Hamm H, Lowe NJ: Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002;147:1218-1226.
3.
Walling HW: Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol 2011;64:690-695.
4.
Bovell DL, Corbett AD, Holmes S, Macdonald A, Harker M: The absence of apoeccrine glands in the human axilla has disease pathogenetic implications, including axillary hyperhidrosis. Br J Dermatol 2007;156:1278-1286.
5.
Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P, Rzany B: Psychosocial aspects of patients with focal hyperhidrosis: marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol 2005;152:342-345.
6.
Skroza N, Bernardini N, La Torre G, La Viola G, Potenza C: Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A. Acta Dermatovenereol 2011;19:16-20.
7.
Hoorens I, Ongenae K: Primary focal hyperhidrosis: current treatment options and a step-by-step approach. J Eur Acad Dermatol Venereol 2012;26:1-8.
8.
Walling HW, Swick BL: Treatment options for hyperhidrosis. Am J Clin Dermatol 2011;12:285-295.
9.
De Campos JR, Hashmonai M, Licht PB, Schick CH, Bischof G, Cameron AE, Connery CP: Treatment options for primary hyperhidrosis. Am J Clin Dermatol 2012;13:139.
10.
Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schaefer I: Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 2011;165:865-873.
11.
Staender S, Schaefer I, Phan NQ, Blome C, Herberger K, Heigel H, Augustin M: Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010;221:229-235.
12.
Schaefer I, Rustenbach SJ, Zimmer L, Augustin M: Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008;217:169-172.
13.
Wörle B, Heckmann M, Rapprich S: Definition and therapy of hyperhidrosis (in German). AWMF, 2012. S1 Guideline, Register No. 013-059.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.